SonoThera, a South San Francisco-based genetic medicine company, announced the initiation of a $125 million Series B financing round at the 44th J.P. Morgan Healthcare Conference. The funding will be directed toward first-in-human studies for three lead indications—Duchenne muscular dystrophy (DMD), autosomal dominant polycystic kidney disease (ADPKD), and X-linked Alport syndrome (XLAS)—using its proprietary RIPPLE ultrasound-mediated delivery platform. Designed to bypass the limitations of viral vectors, RIPPLE enables size-independent, targeted payload delivery using nonviral methods, with a focus on achieving scalable, redosable gene therapy applications.

Why SonoThera’s nonviral platform could reshape the gene delivery paradigm

SonoThera’s delivery model strikes at the core of one of gene therapy’s most persistent bottlenecks: the limitations of viral vectors. Adeno-associated virus (AAV) systems, despite being the industry standard, are constrained by payload capacity (~4.7kb), immunogenicity concerns, and challenges with redosing due to neutralizing antibody formation. These issues particularly affect diseases requiring delivery of large genes—DMD being a textbook example.

SonoThera’s RIPPLE platform, powered by ultrasound-mediated delivery (UMD), promises to overcome these challenges. It uses focused ultrasound and microbubble activation to transiently permeabilize cell membranes, allowing genetic payloads—regardless of size—to enter targeted tissues. What’s notable is that this technique is claimed to be redosable, durable, and compatible with full-length gene delivery, offering a route to treat diseases previously underserved by current vector systems.

From a platform perspective, this is not just another delivery tool. Industry analysts argue that RIPPLE could become the blueprint for a new generation of nonviral, device-enabled gene therapies—especially as regulatory agencies begin to scrutinize viral platforms more closely amid manufacturing and safety incidents.

Full-length dystrophin data raises eyebrows—and expectations

The inclusion of DMD as a lead indication suggests SonoThera is positioning itself to leapfrog the current standard of care. Approved AAV-based DMD therapies like Sarepta Therapeutics’ Elevidys rely on micro-dystrophin constructs due to AAV’s size ceiling. These truncated versions may delay disease progression but are not curative and fall short of restoring full muscle function.

In contrast, SonoThera reports full-length human dystrophin expression in non-human primate skeletal muscle at levels up to 290% of normal, alongside functional rescue of muscle strength in rodent models. If even partially replicated in humans, this would mark a step-change in DMD treatment—unlocking therapeutic efficacy closer to that seen in Becker muscular dystrophy or asymptomatic carriers.

Still, translating such results to humans involves several layers of risk. Clinicians note that full-length dystrophin delivery is only part of the equation—functional integration, immune response, and sustained expression are just as critical. The field has learned from prior gene therapy disappointments that overexpression does not always equal functional rescue, especially when long-term tissue remodeling or fibrosis is involved.

Kidney diseases could test the platform’s precision and breadth

SonoThera’s choice to include ADPKD and XLAS among its early indications suggests confidence in RIPPLE’s ability to deliver to renal compartments, where cell-type specificity and controlled expression are crucial. Targeting kidney cell types like tubular epithelial cells and podocytes has historically been difficult due to anatomical barriers and the need for targeted transduction.

In animal models, SonoThera has demonstrated payload uptake in these cell types, but the translation to human pathology—especially for progressive diseases like ADPKD—requires high bar for delivery precision. Regaining podocyte function, for example, is not just about expressing a protein but ensuring it integrates into the glomerular filtration barrier.

In this context, the company’s siRNA delivery capabilities across muscle, adipose, and kidney tissues may offer additional flexibility. The platform could theoretically support multiple payload formats—mRNA, siRNA, plasmid DNA, or even CRISPR constructs—allowing indication-specific strategies. This modularity could help future-proof the platform, especially as regulatory expectations evolve toward combination therapies and adaptive trial designs.

Regulatory and manufacturing challenges loom as platform enters clinical phase

While the nonviral nature of SonoThera’s platform reduces risks associated with viral vector contamination and immunogenicity, it introduces novel challenges in device regulation, GMP compliance, and combination product classification. Because RIPPLE integrates both a biologic payload and a device delivery mechanism, the platform may be treated as a combination product by the U.S. Food and Drug Administration (FDA).

This classification can significantly complicate the regulatory process. The company will likely need to file under the Office of Combination Products, ensuring that both the drug component and the ultrasound device meet parallel standards of safety and performance. In addition, the redosability claim—one of RIPPLE’s key differentiators—raises questions about longitudinal safety, off-target effects, and device wear-in calibration across diverse patient populations.

Experts familiar with FDA gene therapy trials suggest SonoThera will need to provide robust biodistribution, durability, and immunogenicity data as part of any IND filing. Device calibration, operator dependency, and tissue depth limitations could also come under scrutiny, particularly in indications like DMD where muscle mass and fibrosis vary dramatically with age and disease stage.

Capital deployment and data cadence will determine investor patience

SonoThera’s Series B raise is designed to support a steady cadence of preclinical data through 2028 and the initiation of human trials by early 2027. In today’s capital environment, where genetic medicine startups face growing skepticism due to delivery-related failures and commercial underperformance, SonoThera’s platform narrative must be paired with visible milestones.

To maintain investor confidence, the company will need to rapidly progress IND-enabling studies while transparently disclosing device manufacturing readiness and reproducibility metrics. A key concern will be whether RIPPLE’s delivery efficiency and safety can be maintained at scale and under real-world clinical settings.

Analysts tracking the gene therapy sector believe that successful partnerships—with either large biopharma or medical device manufacturers—could strengthen SonoThera’s commercial outlook. In particular, if the RIPPLE device platform proves customizable for different tissue targets, it could unlock licensing revenue streams outside of in-house programs.

The road to clinic: What the industry will be watching next

As SonoThera prepares for its next phase of growth, several questions remain unresolved. Will RIPPLE’s redosable delivery stand up to repeat administration in humans without triggering inflammatory or fibrotic responses? Can the platform handle payload combinations—such as gene plus editing toolkits—without compromising safety or precision? And will the physical limitations of ultrasound-mediated delivery (e.g., tissue depth, targeting accuracy) restrict the platform’s utility to surface or organ-adjacent tissues?

Beyond the clinic, policy shifts may work in SonoThera’s favor. The FDA and EMA are increasingly focused on delivery innovation, especially in the wake of stalled AAV programs and patient deaths in high-dose systemic trials. A successful demonstration of nonviral, redosable gene delivery could influence not just regulatory frameworks but also academic and commercial platform development across the sector.

If SonoThera delivers on even part of its technical promise, the RIPPLE platform could move from a promising tool to a defining architecture for nonviral gene therapy.

  ADPKD, biotech funding, Duchenne muscular dystrophy, gene therapy, nonviral delivery, rare disease, RIPPLE, SonoThera, ultrasound-mediated delivery, XLAS